Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by New York University School of Medicine
Sponsor:
Collaborators:
Synta Pharmaceuticals Corp.
Memorial Sloan Kettering Cancer Center.
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT02060253
First received: January 30, 2014
Last updated: February 5, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2017
  Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)